View Older Stories View More Recent Stories
-
Form SC 13G/A Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A TG THERAPEUTICS, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A PROTEON THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A AQUINOX PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A DERMA SCIENCES, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Axovant Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ARCA biopharma, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A AveXis, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13D KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS)
-
Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference
-
Satsuma Pharmaceuticals Spins Out from Shin Nippon Biomedical Laboratories (SNBL) with Funding from Leading Institutional Life Science Investors
-
Form SC 13G AveXis, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, LLC
-
Synthorx Appoints Patrick J. Doyle as Chief Business Officer
-
Form 4 KalVista Pharmaceuticals For: Nov 21 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Form SC 13D Ra Pharmaceuticals, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Biohaven Secures $80 Million in Oversubscribed Private Financing to Advance Phase 3 Clinical Trials
-
Biohaven Secures $80 Million in Oversubscribed Private Financing to Advance Phase 3 Clinical Trials
-
Form 4 Ra Pharmaceuticals, Inc. For: Oct 31 Filed by: RA CAPITAL MANAGEMENT, LLC
-
TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007
-
TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007
-
Form SC 13G/A ALCOBRA LTD. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 4 Aclaris Therapeutics, For: Sep 15 Filed by: RA CAPITAL MANAGEMENT, LLC
-
The Economist Presents: "The War on Cancer: Scaling Progress"
-
Form SC 13G Protagonist Therapeutics Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SC 13G Vitae Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
-
KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema
-
Form SC 13G ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Synthorx Announces $10 Million Series B Financing to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
-
Unusual 11 Mid-Day Movers 7/15: (OPTT) (JCTCF) (ITI) Higher; (CYTR) (FMSA) (GBSN) Lower
-
Ardelyx (ARDX) Enters $110M Private Placement
-
Ardelyx to Raise $110 Million in a Private Placement
-
Bay Area Lyme Foundation Announces Finalists of "Lyme Innovation" Hackathon
-
Notable Mergers and Acquisitions 6/15: (EBIX)/(PN) (AEGR)/(QLTI) (DYN) (CBYL) (BBBY)
-
Carbylan Therapeutics (CBYL) Enters Merger Agreement with Privately-Held KalVista
-
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, LLC
-
Antera Raises $1.7M to Help Infants At Risk of Developing Food Allergies
-
KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema
-
Peregrine Communications Expands US Footprint with Suite of New Clients, Key Business Advisors and the Appointment of a New Senior Hire to Bolster Growth
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31

